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The health-related quality of life was not improved
by targeting higher hemoglobin in the Normal
Hematocrit Trial
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The Normal Hematocrit Trial (NHT) was the largest trial
of epoetin randomizing 1265 hemodialysis patients with
cardiac disease to lower (9–11g/dl) or higher (13–15g/dl)
hemoglobin (Hgb), hypothesizing that higher Hgb would
reduce mortality, and improve survival and quality of life. The
trial was terminated early, and a 1998 publication reported
that targeting higher hematocrit levels led to an insignificant
increase in the primary end points (death or myocardial
infarct), or risk ratio 1.3, 95% confidence interval (CI),
0.9–1.90, but the P-value was not given, and all-cause death
risk was not reported. A higher target reportedly did not
increase hospitalization rates, but did significantly improve
the ‘physical function’ domain of quality of life. Comparing
the 1996 Food and Drug Administration (FDA)-filed clinical
trial report to the 1998 publication, however, found several
discrepancies. Among these, the 1998 article reported
interim trial results with only the adjusted CI but did not state
that the unadjusted CIs were 99.912th percentile, and despite
being a secondary end point, reported only the association of
achieved Hgb with higher quality of life score. Randomization
to the higher target had actually increased the risk for
the primary end point (risk ratio 1.28, 95% CI¼ 1.06–1.56;
P¼ 0.0112; 99.92% CI¼ 0.92–1.78), the risk of death (risk ratio
1.27, 95% CI¼ 1.04–1.54), non-access thrombotic events
(P¼ 0.041), and hospitalization rate (P¼ 0.04), while ‘physical
function’ did not improve (P¼ 0.88). Hence, disclosure of
these results in the 1998 publication or access to the FDA-
filed report on the NHT in the late 1990s would likely have
led to earlier concerns about epoetin safety and greater
doubts about its benefits.
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There has been controversy over the risks and benefits of
erythropoietic-stimulating agent (ESA) therapy since the
completion of the Normal Hematocrit Trial (NHT) in 1996
and its publication in 1998.1 The NHT remains the largest
randomized trial of ESA in hemodialysis patients. It treated
patients with clinical evidence of heart failure or ischemic
heart disease with epoetin (an ESA) to a target hematocrit of
30±3% vs. 42±3%. Hematocrit was calculated by multi-
plying the measured hemoglobin (Hgb) level by three. A
majority of the US dialysis patients have ischemic heart
disease or heart failure.2–4 Therefore, the NHT represented an
important assessment of the risks and benefits of higher Hgb
for the majority of dialysis patients.
The NHT was stopped early because of a trend toward
increased deaths and nonfatal MI in the high-Hgb target
arm.1 Although the NHT trial results demonstrated satisfac-
tory outcomes with a Hgb target of 9–11 g/dl, subsequent
nephrology anemia guidelines in 1997 and 2001 recom-
mended a Hgb target of 11–12 g/dl when prescribing an
ESA.5,6 This was largely based on studies suggesting other
benefits from somewhat higher Hgb, including improvements
in health-related quality of life (HRQOL). The NHT
publication stated that higher Hgb had significantly increased
scores in the ‘physical function’ domain of HRQOL. As the
NHT is the largest trial of ESAs in hemodialysis, the report of
improvements in physical function via higher Hgb had a great
impact on clinical guidelines that attempted to balance the
risks and benefits of ESA therapy.
By 2006, the improvement in HRQOL observed in the
NHT was of central importance, as the US and European
Renal guidelines recommended that all patients with chronic
kidney disease (CKD) should have Hgb maintained at 11 g/dl
or higher.7,8 The 2006 US Kidney Disease Outcome Quality
Improvement (KDOQI) guideline group concluded that
‘yQOL (quality of life) is a sufficient and, apparently, the
sole determinant of treatment benefit.’7
Also in 2006, trials in non-dialysis CKD and other
populations reported increased thrombovascular and cardio-
vascular events and death with ESA use, especially when
targeting higher Hgb.9–12 Consequently, the US regulatory
authorities recommended lower Hgb goals and far more
caution when using ESA.12,13 In 2009, the TREAT trial, which
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compared placebo treatment to ESA therapy targeting a Hgb
goal of 13 g/dl, demonstrated that ESA therapy afforded no
reduction in cardiac events or deaths, a marginal improve-
ment in quality of life, and an increased risk of strokes and
arterial and venous thromboembolic events.14
Recently, the Food and Drug Administration (FDA)
concluded that ‘Using ESAs to target a Hgb level of greater
than 11 g/dl increases the risk of serious adverse cardiovas-
cular events and has not been shown to provide additional
patient benefit.’15 This is in conflict with the NHT results
from 1998, which reported that a higher Hgb target improved
HRQOL and insignificantly increased deaths.
I sought to determine whether the results of the NHT
published in 1998 were complete and supported the recom-
mendations in renal anemia guidelines. I obtained the NHT
report filed by Amgen (Thousand Oaks, CA) with the FDA in
1996 through a Freedom of Information Act request, and
compared the primary and secondary predefined HRQOL
end-point results in the Amgen clinical trial report (ACTR)
with the 1998 publication.
RESULTS
The trial randomized 1265 patients, although the 1998
publication and most of the ACTR analyzed data on the 1233
patients who were part of the last interim analysis performed
by the data safety monitoring board.1,16 The clinical trial
report states on page 4 that analyses on the entire 1265
patients did not change the results. The primary end-point
results on the entire 1265-patient cohort were reported in a
letter published in 2008.16
The differences in the major primary and secondary end
points and adverse events between the 1998 publication and
the ACTR are shown in Table 1. Table 1 also compares the
ACTR and the FDA safety announcement on ESAs released
in June 2011 with the 2008 letter containing final NHT
information. The major differences regarding the primary
end point are owing to the 1998 report and the 2008 letter
exclusively reporting adjusted 95% confidence intervals
(CIs), and not providing the P-value for the analysis, which
would have been o0.05.1,16 As shown in the ACTR on pages
54 and 58, the unadjusted CIs required for significance were
99.912% at the last interim analysis (P¼ 0.00088) and
99.92% (P¼ 0.0008) at study termination. As described in
the methods of the original publication, these CIs were
adjusted to account for repeated testing by the data safety
monitoring board. Differences between the treatment groups
with respect to both the primary end point and all-cause
death are statistically significant by the unadjusted CIs, but
fail to reach significance using the boundary rules adopted by
the data safety monitoring board. Stopping the trial early
before reaching the prescribed significance threshold created
an insignificant difference between arms. In 2007 and 2011,
the FDA reported only the unadjusted 95% CIs, and now
classifies the trial results as showing significant harm.15
The 1998 publication states that ‘There were no
differences between groups in the incidence of cerebrovas-
cular accidents, transient ischemic attacks, peripheral gang-
rene, (or) intestinal ischemiay.’ Because of the concern that
epoetin dosed to correct anemia could increase throm-
botic events, the ACTR states on page 78 that there was a
Table 1 | Comparison of 1998 and 2008 New England Journal articles to the FDA-filed NHT Clinical Trial Report
1998 New England Journal of Medicine publication FDA-filed Clinical Trial Report
Data reported The last interim analysis performed on March 30, 1996 on
1233 patients
The last interim analysis performed on March 30, 1996 on
1233 patients
Primary end point
(death+nonfatal MI)
RR 1.3; (95% CI 0.9–1.9). (P-value not given)
95 % CI adjusted for the previous interim analyses
RR 1.3 (99.912% CI=0.92–1.85) (P=0.0119)*,
a
All-cause deaths Not reported Kaplan–Meier, log-rank test P=0.0188*
RR 1.26 (95% CI=1.02–1.56)*,
a
Hospitalization rate 72% vs. 69% P=0.29 by Fisher’s exact test 72% vs. 69% P=0.04 by Kaplan–Meier curve, log-rank test.
Adjustment for covariables, RR 1.14, 95% CI 0.994–1.30
(P=0.06)
Quality of life Physical function domain ‘at 12 months increased by 0.6
point for each percentage-point increase in the hematocrit
(P=0.03).’
None of seven domains showed any significant
improvement over time or between groups
Thrombotic events Vascular access 39% vs. 29%, P=0.001
Other thrombotic events, listed individually, P=NS
Vascular access 39% vs. 29%, P=0.001
Other thrombotic events, grouped, 22% vs. 18%, P=0.041
Final trial results 2008 New England Journal of Medicine Letter to the Editor FDA-filed Clinical Trial Report
Data reported Data reflect the final results on 1265 patients following trial
termination on June 24, 1996.
Data reflect the final results on 1265 patients following
trial termination on June 24, 1996.
Primary end point
(death+nonfatal MI)
RR 1.28 (CI 0.92–1.78); P-value not given. The 95% CI were
adjusted for the previous interim analyses with the use of the
method of repeated confidence intervals.
Kaplan–Meier log-rank P=0.01138. Unadjusted OR 1.28
(99.92% CI=0.92–1.78) (0.0112)**,
a
Abbreviations: CI, confidence interval; FDA, Food and Drug Administration; MI, myocardial infarct; NS, not significant; RR, relative risk.
*The P-value required for significance at this interim analysis was set at 0.00088.
**The P-value required for significance at this analysis was set at 0.0008.
aThe final trial result for relative risk for the primary end point was 1.28, 95% CI 1.06–1.56, and for all-cause death was 1.27, 95% CI 1.04–1.54.
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predefined category of ‘other thrombotic events’, which
included strokes, peripheral arterial thrombosis, and embo-
lism but excluded myocardial infarcts and access thrombosis.
According to the ACTR, page 79, patients randomized to the
higher target experienced significantly more ‘other thrombo-
tic events’ (22.4 vs. 17.6%, P¼ 0.041).
The HRQOL was measured at baseline and at 6-month
intervals. Approximately 857 patients had data reported at
any time point in the HRQOL results tables. In the 1998
publication, there were 961 and 849 patients in the trial at
6 months and 9 months, respectively. The 1998 publication
reported the HRQOL changes as follows: ‘The physical-
function score on the quality-of-life questionnaire at 12
months increased by 0.6 point for each percentage-point
increase in the hematocrit (P¼ 0.03). For example, an
increase in the hematocrit from 30 percent to 42 percent
was associated with a clinically meaningful increase of 7.2
points in the score on the physical-function scale. There were
no significant changes in the scores on the other seven scales.’
The ACTR reports on page 149 the 12-month physical
function score as 35.0±27.3 in the high arm and as
35.0±27.5 in the low arm, P¼ 0.97. Figure 1 graphically
presents the ACTR mean scores for ‘physical function’ domain
at baseline, 6, 12, and 18 months along with the average
hematocrit, epoetin dose, and P-values for group differences
at each time point. The ACTR states that (page 70) ‘There
were no statistically significant changes in quality-of-life
scores between groups or over time.’ Table 2 shows table A-11
of the ACTR report, the area under the curve results, which
was the primary end-point analysis for HRQOL.
Table 3 reproduces the results in the ACTR tables A-12 and
A-13, which ‘show the mean scores for the seven scales at
each 6-month time point, by treatment group.’ The
ACTR summarizes the HRQOL on page 70 as ‘There were
no significant differences between Group A and Group
B scores at any time, and scores did not change significantly
over time.’
According to the ACTR on page 38, differences in
hospitalization rates between groups were to be compared
using the Kaplan–Meier curve and the log-rank test and fitting
Cox proportional hazards regression models. Instead, the 1998
publication reported no difference in hospitalization rates
between groups when compared using Fisher’s exact test
(Table 1). The ACTR provides hospitalization rates identical to
the 1998 publication, but on pages 66 and 67 reports the time
to first hospitalization results in the following manner:
‘Kaplan-Meier curves for time to first hospitalization, show(ed)
that Group B (lower hematocrit target) patients experienced
higher hospitalization-free ‘survival’ compared to Group A
(higher hematocrit target) patients (P¼ 0.04; log rank test)y’.
After adjusting for multiple covariables ‘the RR of hospitali-
zationywas 1.14, but the CI spanned 1.00 (0.99 to 1.30).’
DISCUSSION
This report documents several differences between the
original publication of the NHT trial result in 1998 and the
ACTR filed with the FDA in 1996. The NHTwas intended to
assess the risk/benefit of targeting higher Hgb.1 Unadjusted
mortality and the primary end point of mortality plus
nonfatal myocardial infarcts were significantly higher in the
high target arm. These results were not a complete surprise to
the company, as the ACTR states on page 21 that a rationale
for the trial was an ‘increased risk of mortality (was)
considered among the potential adverse effects of full
correction of anemia in dialysis patients’. The original
publication presented these results as insignificantly different
because of adjustment of the CIs for repeated reviews by the
data safety board monitoring, and this was approved by the
journal’s editors.1,17 Unadjusted statistical results were not
reported in the 1998 publication on the last interim analysis,
or in a published letter in 2008, which provided the final trial
results.16 The FDA now reports in ESA package inserts that
the NHT found significantly higher relative risk when
targeting higher Hgb for both all-cause mortality (1.27,
95% CI 1.04–1.54) and the primary end point (1.28, 95% CI
1.06–1.56). These CIs are not adjusted.15
On the basis of the ACTR results, compared with a Hgb
target of 9–11 g/dl, targeting 13–15 g/dl increases the risk of
graft and fistula thrombosis (P¼ 0.001) and other thrombo-
tic events (P¼ 0.04), accelerates the time to first hospitaliza-
tion (P¼ 0.04), and tends to increase all-cause mortality
(P¼ 0.0188; HR 1.26, 95% CI 1.02–1.56). The sole benefit
was a reduction in the proportion of patients transfused
(P¼ 0.001), whereas HRQOL domains did not improve.
The NHT remains the largest ESA trial in the hemodialysis
population. The trial population characteristics—42% black,
44% with diabetic nephropathy, and 28% with hypertensive
nephropathy, with a mean age of about 65 years, and a mean
time on dialysis of 3 years—are comparable to those of the
prevalent US dialysis population.1,18 In addition, a majority
of the US dialysis patients have cardiac disease, as did all
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Figure 1 |Mean scale scores for physical function domain over
time in high (black circle) and low (open circle) target arm, as
mean±s.d. Hematocrit values, and mean epoetin doses (from
intravenously treated patients), are also from the trial report. From
Amgen clinical trial report pages 119, 120, 126, 127, and 149.
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Table 2 | The primary analysis of changes in HRQOL, the area under the curve results, for each scale determined over 18
months
Group A (high target arm) Group B (low target arm)
HRQOL scale n Mean±s.d. n Mean±s.d. P-value
Primary end points
Vitality 424 45.1±19.6 427 43.6±19.8 0.25
Physical function 423 36.2±24.5 426 36.0±25.0 0.88
Mental health 424 69.3±19.6 426 69.8±18.9 0.72
Secondary end points
Body pain 426 57.0±24.5 428 57.4±24.5 0.83
Physical role 422 34.6±34.8 429 35.3±34.7 0.78
Emotional role limitations 416 57.2±38.1 419 60.1±37.1 0.25
Social function 427 65.5±24.2 428 66.6±23.8 0.49
Abbreviation: HRQOL, health-related quality of life.
Death and missing values were assigned a last value carried forward. There are no significant differences in scores between groups in any scale. From ACTR pages 70 and 148.
Table 3 | The mean scale scores for primary end points (vitality, physical function, and mental health) and secondary
end points over time
Group A (high target arm) Group B (low target arm)
HRQOL scale n Mean±s.d. n Mean±s.d. P-value
Vitality
Baseline 425 44.5±22.0 429 44.7±21.8 0.90
6 months 425 46.0±22.3 429 44.3±22.3 0.26
12 months 425 44.8±21.9 429 43.0±22.2 0.23
18 months 424 44.3±21.8 427 42.0±21.8 0.13
Physical function
Baseline 424 38.6±26.7 428 38.6±27.5 0.99
6 months 424 37.0±26.7 428 36.8±27.7 0.95
12 months 424 35.0±27.3 428 35.0±27.5 0.97
18 months 423 34.9±26.5 426 35.9±26.9 0.56
Mental health
Baseline 425 70.3±20.7 428 69.9±20.6 0.78
6 months 425 69.1±21.2 428 70.3±20.9 0.40
12 months 425 69.0±21.9 428 69.5±21.3 0.73
18 months 424 68.8±21.4 426 68.8±21.3 0.98
Body pain
Baseline 427 58.3±27.4 430 58.7±28.2 0.85
6 months 427 57.6±27.5 430 58.7±27.6 0.57
12 months 427 56.2±27.9 430 56.7±27.9 0.79
18 months 426 56.0±28.2 428 55.4±27.7 0.74
Physical role limitations
Baseline 423 33.1±38.9 431 33.3±38.5 0.95
6 months 423 36.5±41.0 431 36.0±41.4 0.87
12 months 423 33.9±41.0 431 34.9±40.5 0.72
18 months 422 33.2±41.1 429 35.7±40.3 0.38
Emotional role limitations
Baseline 417 56.4±44.3 421 59.7±43.5 0.28
6 months 417 57.7±44.6 421 60.1±43.6 0.43
12 months 417 56.8±44.4 421 59.1±44.6 0.44
18 months 416 57.0±44.8 419 61.6±43.6 0.14
Social function
Baseline 428 65.0±27.8 430 66.4±27.5 0.48
6 months 428 65.5±27.2 430 67.7±28.0 0.23
12 months 428 65.3±28.2 430 65.9±27.9 0.74
18 months 427 66.1±27.7 428 65.5±27.8 0.76
Abbreviation: HRQOL, health-related quality of life.
There are no significant differences in scores between groups at any time, and scores did not change significantly over time. Death and missing values were assigned a last
value carried forward. From ACTR pages 70, 149, and 150.
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the patients in the NHT.2–4 As higher Hgb associates with
improved survival, lower cardiac event rates, and higher
HRQOL, it was hypothesized that raising Hgb would lead to
improved outcomes. The NHT was designed to test this
hypothesis.1 The surprising results suggesting harm from
targeting higher Hgb represented the first major evidence of
safety problems with the use of ESAs.
In 1997, following early termination of the NHT but before
publication of the results, the National Kidney Foundation’s
Dialysis Outcomes Quality Initiative (DOQI, now KDOQI)
guidelines recommended a Hgb goal of 11–12 g/dl when using
an ESA in CKD patients, with physicians determining which
patients warranted treatment.5 The 1997 KDOQI workgroup
was aware that the NHT had been terminated early because
the high target arm ‘was experiencing a greater incidence of
nonfatal myocardial infarcts or death’ than the control arm.5
The 1997 KDOQI guideline and 2001 update did not have the
formal evidence rules and rigid evaluation techniques that are
now commonly used to develop guidelines.5,6 Consequently,
both observational data and trials of varying quality were
considered in support of guidelines. There was also no
substantive emerging evidence of safety problems with ESAs
in patients with renal disease or other populations until later.
In addition, there was a prevailing viewpoint that higher Hgb
was conferring distinct benefits in cardiovascular health and
patient stamina based on observational data and small trial
results. Similarly, the January 2001 updated guidelines used
very similar logic and cited almost identical strands of
evidence to again recommend a Hgb target of 11–12 g/dl when
using epoetin.6 The 2001 update additionally cited a lower
rate of hospitalization when targeting higher Hgb, which
would have been undermined by publication of the ACTR
results noted here.6 Regardless, it is unlikely that knowledge of
the results outlined in this paper would have significantly
altered either the 1997 or the 2001 KDOQI guidelines because
of the lack of corroborating evidence of harm from ESAs.
In contrast, by 2006, there was evidence that ESAs
increased thrombovascular risks and increased deaths in
some cancer trials.9 In addition, some of the earlier proposed
benefits from targeting normal Hgb, such as further
regression of left ventricular hypertrophy, had failed to
materialize in randomized trials.19 Most importantly, the
2006 KDOQI Anemia guidelines were far more rigorous
evaluations of evidence.7 Only clinical trials were considered
evidence, the quality of each trial was assessed, and pertinent
results were collected into evidence tables.
On the basis of review of the evidence tables, the 2006
workgroup wrote a Clinical Practice Guideline that ‘In
patients with CKD, Hb (hemoglobin) should be 11.0 g/dl or
greater.’7 This was a substantive change from previous
guidelines, which had physicians determine whether anemia
warranted treatment. A Clinical Practice Guideline, unlike
practice recommendations, can form the basis for clinical
performance measures to evaluate physicians.20 The work-
group stated that ‘In developing the statement Hb level should
be 11.0 g/dl or greater, the Work Group concluded that—
when comparing higher with lower Hb targets—QOL is a
sufficient and, apparently, the sole determinant of treatment
benefit’ (italics in the original).7
The 2006 KDOQI Hgb target guideline was based solely
on review of interventional trial results. The workgroup cited
five high-quality trials in support of HRQOL claim; by far the
largest was the 1998 NHT publication (Table 4).7 The NHT
results were described as ‘Physical: þ (better with higher
Hgb), Increased by 0.6 point for each percentage point
increase in Hct’, as quoted from the 1998 publication.7 Two
of the other trials reported no significant improvement in
HRQOL when targeting higher vs. lower Hgb.21,22 The other
two high-quality trials, limited to healthier hemodialysis
patients, had conflicting results regarding improvement in
HRQOL.19,23 One found no improvement in any SF-36
measure with higher Hgb targets, but did find improvements
Table 4 | Results from high-quality trials assessing effect of hemoglobin target on HRQOL
Trial
Population, patient
characteristics Numbera
High vs. low hemoglobin
target (g/dl)
Positive HRQOL
differences between arms
Support 2006 hemoglobin
target of 11 g/dl or higher?
Besarab et al.1 Hemodialysis, all had heart
failure or CAD
1233 9–11 vs. 13–15 None (improved physical
function according to 1998
publication)
No
No significant difference
between groups
CanEPO21 b Hemodialysis, all had LVD or
LVH
78 9.5–11 vs. 11.5–13 None No
Foley et al.23 Hemodialysis, free of marked
comorbidity
94 9.5–10.5 vs. 13–14 Fatigue, depression,
relationships
Possibly in healthier subjects
Parfrey et al.19 Hemodialysis, no CAD or LVD 324 9.5–11.5 vs. 13.5–14.5 Vitality Possibly; significantly
increased risk of stroke
Roger et al.22 CKD stage 3 and 4, excluded
uncontrolled angina, class III or
IV HF, severe chronic respiratory
disease, symptomatic peripheral
vascular disease, or fistula
placement
155 9–10 vs. 12–13 None No
Abbreviations: CAD, coronary atherosclerotic disease; CKD, chronic kidney disease; HF, heart failure; HRQOL, health-related quality of life; LVD, left ventricular dilation;
LVH, left ventricular hypertrophy.
aData are extracted from the 2006 KDOQI Anemia guideline evidence tables 13 and 17. Data from only high-quality trials are shown.
bThis trial had a 40-patient third arm, which received placebo; both treatment arms had improvements in HRQOL compared with placebo.
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on other HRQOL instruments,23 whereas the other trial
found an improvement in Vitality domain scores that
persisted for the first 72 of the 96 weeks.19 This last trial
also reported a higher stroke rate (4% vs. 1%, P¼ 0.048) with
targeting higher Hgb.19 Four lower-quality trials of 253, 35,
14, and 10 patients were also cited, but none used the SF-36;
two of these did not use active treatment in one arm, further
limiting their utility.7 The workgroup concluded that ‘This
evidence supports the conclusion that patients treated to a
Hb target greater than 11.0 g/dl likely will experience
measurable QOL benefits with little or no increase in AEs
compared with treatment at lower Hb levels.’7 The ACTR
results greatly undermine this conclusion (see Table 4) and
consequently it is likely that the 2006 KDOQI recommenda-
tions would have been more conservative, and would
certainly not have qualified as a Clinical Practice Guideline.
In retrospect, it is apparent how a guideline group could
be misled by the 1998 publication. In the methods, the 1998
publication stated that HRQOL would be assessed as a
secondary end point, but the results section provides a
description of the association of achieved hematocrit to
improved ‘physical function’ within a treatment arm. In
describing the association of higher Hgb with higher ‘physical
function’, the 1998 publication offers as an example of the
magnitude of the improvement a comparison of hematocrit
values of 42% and 30%, the two hematocrit values that
correspond to the two targets in the study. This gives the
incorrect impression that being randomized to a hematocrit
of 42%, rather than 30%, increases the ‘physical function’
score by 7.2, and that the P-value (0.03) refers to the
comparison between treatment groups. The results from the
ACTR presented here show that randomization to the higher
target did not improve any parameter of HRQOL.
Targeting an intermediate Hgb of 11–12 g/dl in hemodia-
lysis patients with cardiac disease, as KDOQI recommended
in a 2007 update, would lead to a smaller or insignificant
reduction in transfusion rates than those observed in the
NHT. We lack trial data on whether an intermediate target
with ESAs mitigates the harm observed with higher targets.
The CHOIR trial in patients with Stage 3 and 4 CKD used
ESA treatment to target Hgb to 11.3 vs. 13.5 g/dl, and found
an increased risk of cardiovascular events and death with the
higher target.10 The placebo-controlled TREAT trial reported
a significant increase in thrombotic events and strokes with
ESA use, and case–control studies support the fact that ESA
use increases strokes.14,24 Therefore, it is unclear whether
lowering the Hgb target while using ESA reduces stroke risk.
Consequently, a target above 11 g/dl but below 13 g/dl appears
to provide marginal benefits and poses indeterminate risks.
Healthier dialysis patients have significantly higher baseline
vitality scores on the SF-36 than reported in the NHT, and
may experience some temporary improvement in vitality with
higher Hgb.19,25 In contrast, in the NHT even at 6 months,
after a mean 3 g/dl increase in Hgb and before substantial
separation of the mortality curves, there was no significant
improvement in vitality or other HRQOL domains. In
addition, although KDOQI guideline groups and many in
the nephrology community consider the results of trials of
higher Hgb targets as indicative of improving quality of life,
the FDA considers the results unconvincing, noting that the
three largest trials comparing Hgb targets showed that ‘ythe
overall quality-of-life effects were small and inconsistent’.26
These HRQOL improvements were seen in trial arms that
significantly increased the risk of cardiovascular events or
death.1,10,14 Consequently, the FDA has stated that ‘Using
ESAs to target a Hgb level of greater than 11 g/dly has not
been shown to provide additional patient benefit.’6
Four of the authors of the 1998 publication were Amgen
employees, and undoubtedly had access to the ACTR to
prepare the article. Four other authors had only academic
affiliations, and their knowledge of this information is
unknown. To assure complete and balanced presentation of
industry-funded randomized trial results, all authors should
be required to review the complete clinical trial report and
confirm in writing that the manuscript reflects a complete
reporting of the safety and efficacy data. In addition, all
clinical trial reports filed with the FDA on all approved drugs
should be made freely available within a year or two of trial
completion. Alternatively, guideline groups should obtain
trial reports on all major studies under review from the FDA
via the Freedom of Information Act. To assure impartial
review, trial report data should be extracted and confirmed
by external expert reviewers who have no connections to the
pharmaceutical industry or the guideline organization.
On the basis of these complete results on the NHT, in
hemodialysis patients with ischemic heart disease or heart
failure, there are no compelling benefits from targeting Hgb
to above 11 g/dl with ESAs.
MATERIALS AND METHODS
A Freedom of Information Act request was submitted on January 26,
2008 for the report on the NHT filed by Amgen with the FDA
following termination of the trial in 1996. The ACTR was received
1260 days later on July 11, 2011. Statements that are verbatim from
the ACTR are in quotes in this publication, followed by the ACTR
page number or the ACTR’s unnumbered five-page synopsis. The
ACTR was available to this Journal’s reviewers and editors
throughout the review and approval process. Select extracts of the
report are available by emailing DCoyne@dom.wustl.edu and placing
‘Amgen NHT Trial Report’ in the subject line. The report may also be
obtained through a Freedom Of Information Act request to the FDA
for the 1996 Epoetin Alfa clinical study report EPO-930107.
I extracted information on the primary and secondary end points
of the trial, and the final results as reported in the ACTR. Results
were compared with the 1998 publication and references to the NHT
in the National Kidney Foundation’s Kidney Disease Outcomes
Quality Initiative (KDOQI) anemia guidelines published in 1997,
2001, and 2006.
The trial design, baseline characteristics, and treatment goals are
outlined in the original publication.1 Briefly, hemodialysis patients
with clinical evidence of heart disease (history of heart failure or
ischemic heart disease) who were already receiving epoetin and had
stable Hgb of 10–11 g/dl (hemocrit 30–33%) were randomized to a
higher or lower Hgb target. The higher target (Group A) received a
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1.5-fold increase in epoetin dose, followed by further increases at 2-
week intervals as needed to reach a target of 14±1 g/dl. Those
randomized to the lower target (Group B) had epoetin doses
adjusted to maintain a Hgb level of 10±1 g/dl. Contrary to the
trial’s name, Hgb—not hematocrit—was determined, and hemato-
crit was calculated by multiplying the Hgb level by three.
According to the ACTR, page 2, ‘The primary objective of this
study was to assess the effects of the two hematocrit targets, 42 and
30%, on morbidity and mortality in dialysis patients with clinically
evident cardiac disease who were receiving Epoetin alfa therapy.
Quality of life was also evaluated.’ The primary end point was death
and nonfatal myocardial infarct. ‘Secondary end points included all-
cause mortality alone, MI alone, all-cause hospitalization, congestive
heart failure (CHF), unstable angina, coronary artery bypass graft,
(CABG), percutaneous transluminal coronary angioplasty (PTCA),
quality of life, and transfusions, as well as changes in cardiac
medications.’(ACTR, page 38). ‘All-cause mortality alone and all-
cause hospitalization were also compared between treatment groups
using the log-rank test and fitting Cox proportional hazards
regression models. Other secondary end points such as acute MI,
CHD, unstable angina, CABG, PTCA, and transfusions were
compared between groups using chi-square tests.’ (ACTR, page 38).
The ACTR stated on pages 44 and 45, ‘Health related Quality of
Life (HRQOL) Study’: ‘Patients completed a quality-of-life ques-
tionnaire (the Medical Outcomes Study 36-Item Health Survey
[SF-36]) at baseline and every 6 months. The SF-36 is a medical
outcomes instrument that has been validated in prior studies of
ESRD patients.’ ‘The primary HRQOL end points chosen prospec-
tively for this study were the vitality scale, the physical function
scale, and the mental health index scale. Secondary end points were
the bodily pain scale, the physical role limitation scale, the
emotional role limitations scale, and the social function scale. Area
under the curve was calculated for an 18-month period. The last
known value was carried forward for missing data.’
The ACTR also stated on page 78 that a ‘general category of
‘other thrombotic events’ was (prospectively) established because
there was concern regarding the use of epoetin to correct anemia
and these outcomes.’
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